Skip to main content

Advertisement

Table 1 Baseline characteristics of the study population (n = 165)

From: Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis

Characteristic Value
No. female (%) 95 (57.6)
Median age, years (range) 58.8 (19–85)
Median duration of symptoms, months (range) 3 (1–12)
No. with disease duration of 3 months or less (%) 87 (52.7)
Median number of joints with synovitis (range) 10 (3–58)
No. fulfilling at least four ACR criteria for RA (%) 133 (80.6)
Mean M-HAQ score (range) 0.93 (0–2.75)
No. with M-HAQ score ≥ 1.0 (%) 77 (47.0)
Median DAS28-3 score (range) 5.01 (2.09–7.85)
No. with RF ≥ 40 IU/mL (%) 68 (41.2)
No. with anti-CCP ≥ 20 U/mL; positive (%) 53 (33.1)
No. with positive anti-Sa antibodies (%) 46 (28.0)
No. with CRP ≥ 8.0 mg/L (%) 119 (72.6)
No. with at least one HLA-DR 'shared epitope' (%) 77 (47.0)
No. with two HLA-DR 'shared epitopes' (%) 22 (13.4)
Median SvH score (range) 4 (0–54)
No. with total SvH score ≥ 10 (%) 31 (18.8)
No. with erosion SvH score ≥ 5 (%) 30 (18.2)
  1. ACR, American College of Rheumatology; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28-3, Disease Activity Score using 28 joints and 3 variables (tender and swollen joint counts and C-reactive protein); M-HAQ, modified Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor; SvH, Sharp–van der Heijde.